Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 420 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults

NCT00914862
Conditions
Insomnia
Interventions
Ramelteon
Drug
Lead sponsor
Takeda
Industry
Eligibility
6 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Kalamazoo, Michigan
Conditions
Cocaine-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 3 Interventional Results available

Long-Term, Open Label Atomoxetine Study

NCT00190684
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 18 Years
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • El Centro, California + 67 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daily Report Card, Language Intervention
Behavioral · Other
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Add-on citalopram following optimized methylphenidate, Add-on placebo following optimized methylphenidate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
aripiprazole, Sugar pill
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
ADHD, Opioid-Related Disorders, Cocaine Dependence
Interventions
Methylphenidate, Bupropion, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ADHD Collaborative
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Active eTNS, Sham eTNS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 12 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Conditions
ADHD - Combined Type, ADHD, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
Interventions
EYE-SYNC
Device
Lead sponsor
Sync-Think, Inc.
Industry
Eligibility
6 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Carlos, California
Active, not recruiting Not applicable Interventional

tRNS Treatment for ADHD Symptoms

NCT06189703
Conditions
ADHD
Interventions
tRNS
Device
Lead sponsor
Innosphere
Industry
Eligibility
7 Years to 12 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Houston, Texas
Conditions
ADHD
Interventions
SupporT for ADHD and Related Treatment
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Attention Deficit/Hyperactivity Disorder, Emotional Dysfunction, Irritable Mood
Interventions
Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AEVI-001, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E), Stimulant
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Miami, Florida • Buffalo, New York
Conditions
Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD), Attention Deficit Hyperactivity Disorder (ADHD), Schizophrenia Spectrum &Amp; Other Psychotic Disorders, Post Traumatic Stress Disorder, Obsessive Compulsive Disorder (OCD)
Interventions
Solicue Machine Learning Models, Mercuria Machine Learning Models
Diagnostic Test
Lead sponsor
Psyrin Inc.
Industry
Eligibility
13 Years to 60 Years
Enrollment
500 participants
Timeline
2025 – 2026
U.S. locations
2
States / cities
Brookline, Massachusetts • Zanesville, Ohio
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 12 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Completed Phase 2 Interventional Results available

Studying Amphetamine Withdrawal in Humans

NCT01215929
Conditions
Methamphetamine Dependence
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Guanfacine (sustained release)
Drug
Lead sponsor
Neurology Group of Bergen County, P.A.
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ridgewood, New Jersey
Conditions
Attention Deficit Disorders With Hyperactivity
Interventions
Pharmacogenomics report
Diagnostic Test
Lead sponsor
Clinical and Translational Genome Research Institute, Inc.
Other
Eligibility
6 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Hamilton, New Jersey • Mountainside, New Jersey • Toms River, New Jersey
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Challenging Horizons Program
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
14 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Athens, Ohio • Bethlehem, Pennsylvania